The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data
机构：[1]Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China[2]Division of Surgery & Interventional Science, University College London, London, UK[3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[4]Basic and Translational Cancer Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Nsukka, Nigeria
The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume mHSPC.Phase III randomized clinical trials of abiraterone were selected. Individual patient data (IPD) for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy. Survival analysis was performed using Cox hazards model.Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI 0.45-0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1-2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3-4 events increased (RR 1.33). The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All p < 0.05).Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation shouldvalidate these findings in real world setting.PROSPERO: (CRD420251028079).
基金：
This manuscript was funded by the Natural Science Foundation of China [No. 824B2017].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China[2]Division of Surgery & Interventional Science, University College London, London, UK
共同第一作者：
通讯作者：
通讯机构：[2]Division of Surgery & Interventional Science, University College London, London, UK[4]Basic and Translational Cancer Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Nsukka, Nigeria
推荐引用方式(GB/T 7714)：
Zhang Fuxun,Luo Zhirong,Xue Qi,et al.The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data[J].Expert Review Of Anticancer Therapy.2025,1-11.doi:10.1080/14737140.2025.2522981.
APA：
Zhang Fuxun,Luo Zhirong,Xue Qi,Guo Xuyan,Fu Qiang...&Zhang Geng.(2025).The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.Expert Review Of Anticancer Therapy,,
MLA：
Zhang Fuxun,et al."The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data".Expert Review Of Anticancer Therapy .(2025):1-11
：